Gilead's Livdelzi Phase 3 Study Shows Sustained Efficacy, No New Safety Concerns
GILD sits 28% above its 52-week low of $104.46.
Summary
Gilead announced positive further analyses from its Phase 3 ASSURE study for Livdelzi, demonstrating sustained ALP normalization in PBC patients. The drug was also generally well tolerated with no new safety signals observed over two years. This positive late-stage clinical data strengthens Gilead's pipeline and de-risks a potential new treatment, following a period of significant M&A and financing activities for the company.
At the time of this announcement, GILD was trading at $133.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.